Biotronik secures FDA approval for cutting-edge heart rhythm management devices
Biotronik, a German biomedical technology company, has received approval from the US Food and Drug Administration (FDA) for its high-voltage cardiac rhythm management (CRM) devices. ... Read More
Blackstone seals deal to acquire AYUMI Pharmaceutical: A strategic move in Japan’s pharma market
Global investment firm Blackstone has announced the acquisition of AYUMI Pharmaceutical, a leading Japanese specialty pharma company, marking its first controlling private equity investment in ... Read More
X4 Pharmaceuticals completes merger with Arsanis to advance rare disease and cancer treatments
X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases and cancer. This strategic move unites two ... Read More
Eli Lilly completes $8bn acquisition of Loxo Oncology to expand oncology portfolio
Eli Lilly and Company, the US-based pharmaceutical giant, has finalised its $8 billion acquisition of Connecticut-based biopharmaceutical firm Loxo Oncology, a move expected to significantly ... Read More
Blackstone Life Sciences and Novartis launch Anthos Therapeutics to target high-risk cardiovascular diseases
In a strategic partnership aimed at advancing cardiovascular treatments, Blackstone Life Sciences has teamed up with Swiss pharmaceutical giant Novartis to create Anthos Therapeutics, a ... Read More
Vitruvias Therapeutics and Sinotherapeutics team up to launch bioequivalent Rythmol SR in US
Vitruvias Therapeutics, a US-based finished-dose generic drug manufacturer, has announced the US launch of a bioequivalent, FDA-approved version of the antiarrhythmic drug Rythmol SR, in ... Read More
Multiple Sclerosis symptoms may worsen with consumption of Soda, Sugar sweetened beverages
If people with multiple sclerosis consume 290 calories of soda or sugar sweetened beverages a day, their symptoms may worsen as warned by the researchers. ... Read More
SOM Biotech secures €7m for repurposing drugs for rare CNS diseases
Spanish pharmaceutical company SOM Biotech has raised €7 million in a new financing round to support its work in repurposing drugs for orphan diseases of ... Read More
Here’s why the body may reject lung transplants
New Delhi, Mar 05 (ANI): A study led by researchers at Washington University School of Medicine in St. Louis, has identified, in mice, a process ... Read More
Aldevron expands antibody development facility in Freiburg, Germany
Aldevron, a US-based contract development and manufacturing organisation (CDMO), has unveiled plans to expand its antibody development facility located in Freiburg, Germany. The Freiburg site, ... Read More